it is easy as far as it being a 'pristine'' entity
Post# of 36536
"So, it did take longer, but now that the K has finally been filed, we believe
that we're very close now to getting the NuGenerex Immuno-Oncology
public. And I can assure you that it not only benefits shareholders, but it
benefits shareholders not only in NuGenerex Immuno-Oncology once it's
public, but it would benefit NuGenerex's shareholders immensely when it's
public--as well as the company."